Indian Immunologicals Nears Completion of ₹700-Crore Greenfield Vaccine Plant in Hyderabad’s Genome Valley

With exactly two months remaining before its operational deadline, the construction of Indian Immunologicals Limited’s (IIL) state-of-the-art greenfield veterinary vaccine facility in Genome Valley, Hyderabad, has entered its final mechanical and validation stages.

The ₹700-crore mega-facility, which broke ground in late 2023, is on track to hit its August 2026 completion target, promising a vital boost to India’s national livestock biosecurity infrastructure.

Once commissioned, the highly automated plant will add a massive 150 million doses of annual capacity for the Foot and Mouth Disease (FMD) vaccine, along with an additional 150 million doses for the combined FMD + Haemorrhagic Septicaemia (FMD+HS-Vac) formulation, bringing the facility’s total combined output capacity to 300 million doses per annum.

Technical Architecture: BSL-3 Safety and Advanced Fill-Finish

Located on a 14-acre land parcel at Biotech Park, Phase III, Karkapatla (Siddipet district), allotted by the state industrial infrastructure corporation, the greenfield hub is engineered to comply with stringent international regulatory frameworks.

The site features a highly specialized Biosafety Level 3 (BSL-3) containment facility dedicated entirely to the safe handling and manufacture of live drug substances. This is paired with an independent, automated fill-finish line optimized for high-velocity packaging of both specialized vaccine variants.

By keeping the production of the pure FMD vaccine and the combined FMD+HS shot under one roof, IIL will be able to fluidly shift manufacturing lines depending on seasonal disease outbreaks and shifting state-level veterinary requisitions.

Driving the Elimination Goal: Support for the LHDCP

The timing of the plant’s completion is critical for India’s domestic livestock policy. IIL, a subsidiary of the National Dairy Development Board (NDDB), operates as the primary supplier to the Government of India’s flagship Livestock Health and Disease Control Programme (LHDCP).

Historically, FMD and Haemorrhagic Septicaemia have caused severe economic damage to India’s rural economy. FMD triggers a drastic reduction in milk yields across dairy cattle and causes high mortality rates in young calves, costing farmers billions of rupees annually in lost production.

The expansion of domestic vaccine manufacturing volumes directly underpins the central government’s goal of complete disease eradication by the end of the decade.

Macro Outlook: Fueling Domestic and Pan-African Trade

Beyond securing domestic supply chains, the new Genome Valley facility is positioned to act as a launchpad for IIL’s international expansion. The vaccine major already exports essential animal biologicals to over 60 countries across the Middle East, Asia, and Latin America.

With the international animal health community actively monitoring a global rise in transboundary livestock viruses, IIL’s leadership indicates that the company is mapping out future infrastructure investments in high-risk zones, including sub-Saharan Africa. The scaling up of production capacities in Hyderabad will free up immediate volumes, allowing India to step in as a major supplier of affordable, certified multi-valent animal health biologicals on the global stage.